These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30341016)

  • 1. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
    Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
    [No Abstract]   [Full Text] [Related]  

  • 2. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
    Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
    Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
    Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
    JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 7. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
    Xu Y; Fan Y
    Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
    Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
    [No Abstract]   [Full Text] [Related]  

  • 10. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
    Rotow JK; Woodard GA; Urisman A; McCoach CE; Bivona TG; Elicker BM; Jablons DM; Blakely CM
    Clin Lung Cancer; 2019 Mar; 20(2):e137-e141. PubMed ID: 30553716
    [No Abstract]   [Full Text] [Related]  

  • 14. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
    J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
    Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
    van Kempen LC; Wang H; Aguirre ML; Spatz A; Kasymjanova G; Vilacha JF; Groves MR; Agulnik J; Small D
    J Thorac Oncol; 2018 Sep; 13(9):e161-e163. PubMed ID: 29704676
    [No Abstract]   [Full Text] [Related]  

  • 20. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.